June 21, 2018

Chasing the Next Biotech Unicorn

How private equity sets to thrive in the biotech boom in Hong Kong

New listing rules in Hong Kong for biotech and the healthcare reform in China are propelling capital raising activities in the region. Rocketed valuation in the biotech sector drives interest from private equity investments, who demand swift investment cycle with a clear profit-making path for going public. The importance of rigorous and timely pre-investment screening and due diligence process is at an all-time high.

Download this whitepaper to examine the potential opportunities and headwinds in the biotech state-of-play, as well as factors that would drive deal success.

Fill out the form to download this whitepaper.

You may also like:

Deal Drivers: APAC Q1 2022

M&A activity across the APAC region as a whole slipped in Q1, which was to be expected after a record-setting 2021. It’s a trend that can be observed across geographic markets an is best understood as a reversion to the mean rather than a cause for concern at this stage. Learn more from our latest Deal Drivers report.

Deal Drivers: EMEA Q1 2022

After a stellar 2021, M&A markets around the world experienced a return to levels more in line with historic precedent in Q1 2022. EMEA was no exception, with deal values and volumes declining. But bright spots persisted. Find out how EMEA M&A performed in Q1 2022 and what lies ahead for the region.

Deal Drivers: Americas Q1 2022 Report

After the ferocious momentum of 2021, dealmaking in the Americas has been easing down in recent months. Not so much a decline as a return to business as usual, the first quarter of 2022 offers clearer indications of what lies ahead.